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Background: Baseline elevation of troponin I (TnI) has been associated with worse outcomes in heart failure (HF). However, prevalence of chronic 
persistent TnI elevation and its association with clinical outcomes is not well described.
Methods: In 510 patients with initial HF admission between 2002 to 2004, and subsequent hospital admissions up to May 2009, chronic 
persistent TnI elevation was defined as a level ≥ 0.05 ng/ml on ≥ 3 HF admissions. Baseline characteristics and all cause mortality were compared 
between chronic persistent TnI elevation (ChPerTnI) and control (noChPerTnI) groups.
Results: Mean age of our cohort was 68.4 yrs, 99.6% were male, 69% had ischemic etiology, 77.8% had NYHA class III-IV HF, mean LVEF was 25.8 
± 13.4%. Chronic persistent elevation of TnI was present in 40% of the cohort and 86% patients with ≥ 3 HF admissions. Mean TnI level was 1.11 
± 7.25 ng/ml in the ChPerTnI group. Ischemic etiology, hypertension, diabetes, chronic renal insufficiency and age did not differ between the two 
groups. LVEF tended to be lower in ChPerTnI group (25.3±12.3 , 30.0 ± 15.6, p=0.08). ChPerTnI was associated with higher mortality (HR 1.99, 95 % 
CI: 1.06-3.73, p=0.03, adjusted for LVEF) (fig) in the overall cohort.
Conclusions: TnI was chronically and persistently elevated in 40% of the hospitalized HF cohort, and 86% of patients with > 3 HF 
rehospitalizations. Chronic persistence of TnI elevation did not differ according to ischemic etiology, but was associated with higher mortality over 5 
years.
